ArticlePloS one2026
Incidence of depression in patients with psoriasis and psoriatic arthritis treated with biologic therapy: Protocol for a systematic review and meta-analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis and psoriatic arthritis are chronic immune-mediated diseases with both physical and psychological consequences. Depression is a common comorbidity associated with impaired quality of life and lower treatment adherence. Biologics, monoclonal antibodies targeting key cytokines, may favorably influence depressive symptoms by reducing systemic inflammation and improving disease activity. However, current evidence is heterogeneous and has not been comprehensively synthesized.
methodsThis systematic review and meta-analysis will evaluate whether biologic therapy reduces the risk of depression among adults with psoriasis or psoriatic arthritis compared with non-biologic treatment or no therapy. Electronic searches will include MEDLINE, Embase, Cochrane Library, PsycINFO, and ClinicalTrials.gov. Eligible designs are randomized controlled trials (RCTs), cohort, and case-control studies reporting depression incidence or prevalence. Depression may be ascertained through clinical diagnosis or validated instruments. Study selection, data extraction, and risk-of-bias assessment will be performed independently by two reviewers. Using the Cochrane Risk of Bias 2.0 tool and the Newcastle-Ottawa Scale, we will assess quality of each study. Data permitting, random-effects meta-analysis will estimate pooled risk ratios (RRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Certainty of evidence will be rated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. DISCUSSION: This review will synthesize the impact of biologic therapy on incident depression in psoriasis and psoriatic arthritis, informing integrated care for patients with psoriatic disease. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (submitted; registration number to be confirmed prior to data extraction).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.